Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Maidment, Ian
2000.
Use of serotonin antagonists in the treatment of neuroleptic-induced akathisia.
Psychiatric Bulletin,
Vol. 24,
Issue. 9,
p.
348.
Poyurovsky, M.
Nave, R.
Epstein, R.
Tzischinsky, O.
Schneidman, M.
Barnes, T.R.E.
Weizman, A.
and
Lavie, P.
2000.
Actigraphic monitoring (actigraphy) of circadian locomotor activity in schizophrenic patients with acute neuroleptic-induced akathisia.
European Neuropsychopharmacology,
Vol. 10,
Issue. 3,
p.
171.
Caligiuri, Michael P.
Jeste, Dilip V.
and
Lacro, Jonathan P.
2000.
Antipsychotic-Induced Movement Disorders in the Elderly.
Drugs & Aging,
Vol. 17,
Issue. 5,
p.
363.
Lindström, Leif H
2000.
Schizophrenia, the dopamine hypothesis and α2-adrenoceptor antagonists.
Trends in Pharmacological Sciences,
Vol. 21,
Issue. 6,
p.
198.
Poyurovsky, Michael
and
Weizman, Abraham
2001.
Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: A new approach to an old problem.
British Journal of Psychiatry,
Vol. 179,
Issue. 1,
p.
4.
Nelson, D E
2001.
Akathisia — A Brief Review.
Scottish Medical Journal,
Vol. 46,
Issue. 5,
p.
133.
Wood, M.D.
Reavill, C.
Trail, B.
Wilson, A.
Stean, T.
Kennett, G.A.
Lightowler, S.
Blackburn, T.P.
Thomas, D.
Gager, T.L.
Riley, G.
Holland, V.
Bromidge, S.M.
Forbes, I.T.
and
Middlemiss, D.N.
2001.
SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety.
Neuropharmacology,
Vol. 41,
Issue. 2,
p.
186.
POYUROVSKY, MICHAEL
and
WEIZMAN, ABRAHAM
2001.
Mirtazapine for Neuroleptic-Induced Akathisia.
American Journal of Psychiatry,
Vol. 158,
Issue. 5,
p.
819.
Fischel, Tsvi
Hermesh, Haggai
Aizenberg, Dov
Zemishlany, Zvi
Munitz, Hanan
Benjamini, Yoav
and
Weizman, Abraham
2001.
Cyproheptadine Versus Propranolol for the Treatment of Acute Neuroleptic-Induced Akathisia: A Comparative Double-Blind Study.
Journal of Clinical Psychopharmacology,
Vol. 21,
Issue. 6,
p.
612.
Shiloh, R.
Zemishlany, Z.
Aizenberg, D.
Valevski, A.
Bodinger, L.
Munitz, H.
and
Weizman, A.
2002.
Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia.
International Clinical Psychopharmacology,
Vol. 17,
Issue. 2,
p.
59.
Laux, G.
Fritze, J.
König, W.
Dietmaier, O.
and
König, F.
2002.
Neuro-Psychopharmaka Ein Therapie-Handbuch.
p.
103.
Caligiuri, Michael P
2002.
Epidemiology and Management of Acute Antipsychotic-Induced Movement Disorders in the Elderly.
Psychiatric Annals,
Vol. 32,
Issue. 4,
p.
253.
Marthi, K.
Bender, D.
Watanabe, H.
and
Smith, D.F.
2002.
PET evaluation of a tetracyclic, atypical antidepressant, [N-methyl-11C]mianserin, in the living porcine brain.
Nuclear Medicine and Biology,
Vol. 29,
Issue. 3,
p.
317.
Stryjer, Rafael
Strous, Rael D.
Bar, Faina
Poyurovsky, Michael
Weizman, Abraham
and
Kotler, Moshe
2003.
Treatment of Neuroleptic-Induced Akathisia With the 5-HT2A Antagonist Trazodone.
Clinical Neuropharmacology,
Vol. 26,
Issue. 3,
p.
137.
Barnes, Thomas R. E.
2003.
The Barnes Akathisia Rating Scale–Revisited.
Journal of Psychopharmacology,
Vol. 17,
Issue. 4,
p.
365.
Tuisku, Katinka
Virkkunen, Matti
Holi, Matti
Lauerma, Hannu
Naukkarinen, Hannu
Rimon, Ranan
and
Wahlbeck, Kristian
2003.
Antisocial Violent Offenders With Attention Deficit Hyperactivity Disorder Demonstrate Akathisia-Like Hyperactivity in Three-Channel Actometry.
The Journal of Neuropsychiatry and Clinical Neurosciences,
Vol. 15,
Issue. 2,
p.
194.
Poyurovsky, Michael
Epshtein, Svetlana
Fuchs, Camil
Schneidman, Michael
Weizman, Ronit
and
Weizman, Abraham
2003.
Efficacy of Low-Dose Mirtazapine in Neuroleptic-Induced Akathisia: A Double-Blind Randomized Placebo-Controlled Pilot Study.
Journal of Clinical Psychopharmacology,
Vol. 23,
Issue. 3,
p.
305.
2004.
Drug-Induced Movement Disorders.
Vol. 20045530,
Issue. ,
Gross-Isseroff, Ruth
Magen, Ayelet
Shiloh, Roni
Hermesh, Haggai
and
Weizman, Abraham
2005.
The 5-HT1D receptor agonist zolmitriptan for neuroleptic-induced akathisia: an open label preliminary study.
International Clinical Psychopharmacology,
Vol. 20,
Issue. 1,
p.
23.
Franck, N.
and
Thibaut, F.
2005.
Modalités d'utilisation des neuroleptiques.
EMC - Psychiatrie,
Vol. 2,
Issue. 4,
p.
300.
eLetters
No eLetters have been published for this article.